Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

232P - Molecular alterations of interest in anal cancer: Inventory and therapeutic impact, a retrospective study

Date

27 Jun 2024

Session

Poster Display session

Presenters

GAUTIER BOILLET

Citation

Annals of Oncology (2024) 35 (suppl_1): S94-S105. 10.1016/annonc/annonc1479

Authors

G. BOILLET1, C. Smolenski2, S. Pernot3

Author affiliations

  • 1 CHU de Bordeaux-Hôpital Haut-Lévêque, Pessac/FR
  • 2 Institut Gustave Roussy, Villejuif, Cedex/FR
  • 3 Institut Bergonié, BORDEAUX/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 232P

Background

Anal carcinoma’s incidence is rising, and although it is rare, it has a poor survival if metastatic (1). Circulating tumor DNA (ctDNA) could be a less invasive technique to evaluate molecular alteration (2). We aimed to describe patients with anal carcinoma (AC) and MA to estimate their impact on overall survival (OS), and the possibility to receive an early access treatment (targeted or not).

Methods

We centralized liquid biopsies and tissue samples between two French centers. We collected data on demographics, tumor type, previous treatments, HPV status and clinical outcomes. We assessed MA based on ESCAT classification, pan-tumoral, due to the lack of ESCAT classification dedicated to AC. Patients and tumors characteristics were assessed at baseline.

Results

A total of 68 patients were included in the analysis. Our patients were mostly women (57%) aged of 63 years (57;72). Squamous cell carcinomas were the most frequent histology type (61), 22 patients (NA = 39) had p16-positive tumors and 2 patients (NA = 39) were infected with HIV. 26 patients (39%) were metastatic at diagnosis. A total of 39.7% (N = 27) patients showed targetable MA according to ESCAT. Most frequents targetable MA founded were PI3KCA (12), PTEN (5), ATM (5), ERBB2 (2), ERBB3 (1), EGFR (2), ATR (1), FGFR2 (1), POLE (1), and TMB high (19%, N=13). OS among patients with targetable MA did not differ from patients without targetable MA, or in patients who received or not an early access treatment.

Conclusions

Our study found a significant number of patients presenting targetable MA, with no differences in OS between those two groups. It can be explained by the scarcity of accessible studies for these patients during our follow-up. Those findings could emphasize the need for new studies among these patients given the frequency of targetable MA and the development of new-targeted therapy.

Legal entity responsible for the study

Institut Bergonié, Bordeaux, France.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.